Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine
- PMID: 31506309
- PMCID: PMC6737241
- DOI: 10.1128/mBio.01668-19
Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine
Abstract
The human pathogens Neisseria gonorrhoeae and Neisseria meningitidis share high genome identity. Retrospective analysis of surveillance data from New Zealand indicates the potential cross-protective effect of outer membrane vesicle (OMV) meningococcal serogroup B vaccine (MeNZB) against N. gonorrhoeae A licensed OMV-based MenB vaccine, MenB-4C, consists of a recombinant FHbp, NhbA, NadA, and the MeNZB OMV. Previous work has identified several abundantly expressed outer membrane proteins (OMPs) as major components of the MenB-4C OMV with high sequence similarity between N. gonorrhoeae and N. meningitidis, suggesting a mechanism for cross-protection. To build off these findings, we performed comparative genomic analysis on 970 recent N. gonorrhoeae isolates collected through a U.S surveillance system against N. meningitidis serogroup B (NmB) reference sequences. We identified 1,525 proteins that were common to both Neisseria species, of which 57 proteins were predicted to be OMPs using in silico methods. Among the MenB-4C antigens, NhbA showed moderate sequence identity (73%) to the respective gonococcal homolog, was highly conserved within N. gonorrhoeae, and was predicted to be surface expressed. In contrast, the gonococcal FHbp was predicted not to be surface expressed, while NadA was absent in all N. gonorrhoeae isolates. Our work confirmed recent observations (E. A. Semchenko, A. Tan, R. Borrow, and K. L. Seib, Clin Infect Dis, 2018, https://doi.org/10.1093/cid/ciy1061) and describes homologous OMPs from a large panel of epidemiologically relevant N. gonorrhoeae strains in the United States against NmB reference strains. Based on our results, we report a set of OMPs that may contribute to the previously observed cross-protection and provide potential antigen targets to guide the next steps in gonorrhea vaccine development.IMPORTANCE Gonorrhea, a sexually transmitted disease, causes substantial global morbidity and economic burden. New prevention and control measures for this disease are urgently needed, as strains resistant to almost all classes of antibiotics available for treatment have emerged. Previous reports demonstrate that cross-protection from gonococcal infections may be conferred by meningococcal serogroup B (MenB) outer membrane vesicle (OMV)-based vaccines. Among 1,525 common proteins shared across the genomes of both N. gonorrhoeae and N. meningitidis, 57 proteins were predicted to be surface expressed (outer membrane proteins [OMPs]) and thus preferred targets for vaccine development. The majority of these OMPs showed high sequence identity between the 2 bacterial species. Our results provide valuable insight into the meningococcal antigens present in the current OMV-containing MenB-4C vaccine that may contribute to cross-protection against gonorrhea and may inform next steps in gonorrhea vaccine development.
Keywords: Bexsero; MenB-4C; Neisseria gonorrhoeae; Neisseria meningitidis; cross-protection; genetic similarity; outer membrane proteins; outer membrane vesicles; vaccine development.
Figures




Similar articles
-
The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.Clin Infect Dis. 2019 Sep 13;69(7):1101-1111. doi: 10.1093/cid/ciy1061. Clin Infect Dis. 2019. PMID: 30551148 Free PMC article.
-
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.PLoS Pathog. 2020 Dec 8;16(12):e1008602. doi: 10.1371/journal.ppat.1008602. eCollection 2020 Dec. PLoS Pathog. 2020. PMID: 33290434 Free PMC article.
-
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7. Clin Vaccine Immunol. 2010. PMID: 20375242 Free PMC article.
-
Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.Front Immunol. 2019 Apr 9;10:683. doi: 10.3389/fimmu.2019.00683. eCollection 2019. Front Immunol. 2019. PMID: 31024540 Free PMC article. Review.
-
4CMenB journey to the 10-year anniversary and beyond.Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8. Hum Vaccin Immunother. 2024. PMID: 38976659 Free PMC article. Review.
Cited by
-
Insight into Prevention of Neisseria Gonorrhoeae: A Short Review.Vaccines (Basel). 2022 Nov 18;10(11):1949. doi: 10.3390/vaccines10111949. Vaccines (Basel). 2022. PMID: 36423044 Free PMC article. Review.
-
Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria gonorrhoeae Microparticle Vaccine Formulation.Vaccines (Basel). 2022 Jun 21;10(7):983. doi: 10.3390/vaccines10070983. Vaccines (Basel). 2022. PMID: 35891147 Free PMC article.
-
Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C.Front Immunol. 2024 Feb 19;15:1350344. doi: 10.3389/fimmu.2024.1350344. eCollection 2024. Front Immunol. 2024. PMID: 38440731 Free PMC article.
-
Neisseria gonorrhoeae vaccines: a contemporary overview.Clin Microbiol Rev. 2024 Mar 14;37(1):e0009423. doi: 10.1128/cmr.00094-23. Epub 2024 Jan 16. Clin Microbiol Rev. 2024. PMID: 38226640 Free PMC article. Review.
-
Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.J Infect Dis. 2025 Feb 4;231(1):61-70. doi: 10.1093/infdis/jiae383. J Infect Dis. 2025. PMID: 39082700 Free PMC article.
References
-
- Perrin A, Bonacorsi S, Carbonnelle E, Talibi D, Dessen P, Nassif X, Tinsley C. 2002. Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect Immun 70:7063–7072. doi:10.1128/iai.70.12.7063-7072.2002. - DOI - PMC - PubMed
-
- Todar K. 2008. Pathogenic neisseriae: gonorrhea, neonatal ophthalmia and meningococcal meningitis. Todar’s online textbook of bacteriology. http://textbookofbacteriology.net/neisseria.html.
-
- Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC). 2013. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 62:1–28. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources